German biotech firm immatics gets Series C funding
immatics biotechnologies, a German biotechnology firm, has raised EUR54m ($71m) in Series C funding to continue research into a new vaccine to protect against renal cell carcinoma. Half the funding came from return investors dievini Hopp Biotech holding and venture capital firm Wellington Partners, while the rest came from a first-time investor, MIG Verwaltungs AG. Dr. Matthias Kromayer of MIG will join the immatics board.
21 September 2010•6 mins read
